checkAd
    Startseite > Aktien > Aldeyra Therapeutics > Nachrichten
    Aldeyra Therapeutics Aktie
    3,5020
     
    EUR
    -2,21 %
    -0,0790 EUR
    Letzter Kurs 22:26:48 Tradegate
    3,4450
     
    EUR
    1.161 STK
    Geldkurs 22:00:01
    3,5580
     
    EUR
    1.124 STK
    Briefkurs 22:00:01
    ISIN: US01438T1060 · WKN: A111X8 · SYM: 137 · USA

    Neueste Nachrichten

    Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
    08.05.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
    25.04.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
    18.04.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
    28.03.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    06.02.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
    04.01.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
    19.12.23 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
    18.12.23 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
    27.11.23 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
    01.11.23 · Business Wire (engl.) · Aldeyra Therapeutics
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)
    28.09.23 · Business Wire (engl.) · Aldeyra Therapeutics
    ALDEYRA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
    28.09.23 · Business Wire (engl.) · Aldeyra Therapeutics